Literature DB >> 2784194

The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA.

M H Malim1, J Hauber, S Y Le, J V Maizel, B R Cullen.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) replication requires the expression of two classes of viral mRNA. The early class of HIV-1 transcripts is fully spliced and encodes viral regulatory gene products. The functional expression of one of these nuclear regulatory proteins, termed Rev (formerly Art or Trs), induces the cytoplasmic expression of the incompletely spliced, late class of HIV-1 mRNAs that encode the viral structural proteins, including Gag and Env. Here, we provide evidence that this induction reflects the export from the cell nucleus to the cytoplasm of a pool of unspliced viral RNA constitutively expressed in the nucleus. The hypothesis that Rev acts on RNA transport, rather than splicing, is further supported by the observation that the cytoplasmic expression of a non-spliceable HIV-1 env gene sequence is also subject to Rev regulation. Here we show that this Rev response requires a specific target sequence which coincides with a complex RNA secondary structure present in the env gene. The response to Rev is fully maintained when this sequence is relocated to other exonic or intronic locations within env but is ablated by inversion. These results indicate that the HIV-1 rev gene product induces HIV-1 structural gene expression by activating the sequence-specific nuclear export of incompletely spliced HIV-1 RNA species.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784194     DOI: 10.1038/338254a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  561 in total

1.  p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication.

Authors:  J N Harada; A J Berk
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery.

Authors:  N Srinivasakumar; F G Schuening
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

3.  Polyuridylated mRNA synthesized by a recombinant influenza virus is defective in nuclear export.

Authors:  L L Poon; E Fodor; G G Brownlee
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

Review 4.  Nuclear RNA export pathways.

Authors:  B R Cullen
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

5.  Chicken Y-box proteins chk-YB-1b and chk-YB-2 repress translation by sequence-specific interaction with single-stranded RNA.

Authors:  S K Swamynathan; A Nambiar; R V Guntaka
Journal:  Biochem J       Date:  2000-06-01       Impact factor: 3.857

6.  RanGTP-binding protein NXT1 facilitates nuclear export of different classes of RNA in vitro.

Authors:  B Ossareh-Nazari; C Maison; B E Black; L Lévesque; B M Paschal; C Dargemont
Journal:  Mol Cell Biol       Date:  2000-07       Impact factor: 4.272

7.  Prediction of common secondary structures of RNAs: a genetic algorithm approach.

Authors:  J H Chen; S Y Le; J V Maizel
Journal:  Nucleic Acids Res       Date:  2000-02-15       Impact factor: 16.971

8.  Herpes simplex virus ICP27 induces cytoplasmic accumulation of unspliced polyadenylated alpha-globin pre-mRNA in infected HeLa cells.

Authors:  P Cheung; K S Ellison; R Verity; J R Smiley
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

9.  Polyvalent Rev decoys act as artificial Rev-responsive elements.

Authors:  T L Symensma; S Baskerville; A Yan; A D Ellington
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

10.  R region sequences in the long terminal repeat of a murine retrovirus specifically increase expression of unspliced RNAs.

Authors:  A M Trubetskoy; S A Okenquist; J Lenz
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.